Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5BVIFN-beta
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
H5BVIFN-beta is a **lyophilized preparation of High Five (H5) insect cells** transduced with recombinant baculovirus expressing **interferon-beta (IFN-beta)**. It is designed as a local (intratumoral) therapy for cancer: after production, the modified insect cells are injected directly into tumors, where they secrete murine IFN-beta, leading to antitumor effects. In murine models, intratumoral injection of H5BVIFN-beta suppressed the growth of established orthotopic colon cancer and reduced liver metastases. The mechanism involves induction of apoptosis in tumor and endothelial cells, infiltration by immune effector cells (including CD8+ and F4/80+ cells), and upregulation of inducible nitric oxide synthase, resulting in tumor cell death and vascular destruction. The approach is experimental and based on gene therapy/platform delivery using insect cells for local sustained cytokine production[1].
- Other names
- H5BVIFN-βH5BVIFN-betaH-5BVIFN-betaH 5BVIFN-beta
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on H5BVIFN-beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5BVIFN-beta.